查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1607976

骨髓恶性肿瘤检测市场：按产品类型、技术、疾病类型、最终用户划分 - 全球预测 2025-2030

Hematologic Malignancies Testing Market by Product (Consumables, Services, Testing Kits), Technology (Fluorescence In Situ Hybridization, Immunohistochemistry, Next-Generation Sequencing), Disease Type, End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

骨髓恶性肿瘤检测市场2023年估值为33.5亿美元，预计2024年将达36亿美元，复合年增长率为7.82%，到2030年将达56.9亿美元。

骨髓恶性肿瘤检测的范围包括一套旨在识别和表征血癌的诊断和监测工具，包括白血病、淋巴瘤和骨髓瘤。这些测试对于确定特定的癌症类型、评估疾病进展和製定个人化治疗计划至关重要，因此对医疗保健提供者和患者都至关重要。市场应用涵盖临床诊断、研究和个人化医疗，最终用户主要是医院、实验室和研究机构。推动市场成长要素是血癌盛行率的增加以及基因和分子检测技术的进步。此外，对个人化医疗和早期疾病检测的日益关注也推动了对这些测试的需求。最近的技术进步，例如次世代定序和基于 PCR 的方法，为满足对精确和快速诊断不断增长的需求提供了潜在的机会。希望利用这些机会的公司应该透过投资研发来提高测试准确性并降低成本，从而提高可及性。然而，先进测试设备的高成本、监管障碍以及对专业人员的需求等限制因素对市场成长构成了挑战。此外，新兴市场的医疗基础设施和准入方面的差异进一步阻碍了采用。该领域的创新可能来自开发更具成本效益和便携式测试解决方案、增强照护现场诊断以及整合人工智慧和机器学习以更好地解释资料。该市场不断发展的性质反映在其对连接技术进步和临床应用的承诺上。为了保持竞争力，企业应专注于分子诊断、基因检测和生物感测器方面的策略联盟和持续创新，以满足癌症诊断准确性和效率的需求。

主要市场统计
基准年[2023] 33.5亿美元
预测年份 [2024] 36亿美元
预测年份 [2030] 56.9亿美元
复合年增长率（%） 7.82%

市场动态：快速发展的骨髓恶性肿瘤检测市场的关键市场洞察

供需的动态交互作用正在改变骨髓恶性肿瘤检测市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 人口老化和骨髓恶性肿瘤增加
    • 倾向早期诊断和早期治疗
    • 采用免疫疗法和标靶药物
  • 市场限制因素
    • 骨髓恶性肿瘤的治疗费用不断上涨
  • 市场机会
    • 强调个人化医疗方法
    • 全球临床试验数量增加
  • 市场挑战
    • 与骨髓恶性肿瘤相关的副作用

波特五力：驾驭骨髓恶性肿瘤检测市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解骨髓恶性肿瘤检测市场的外部影响

外部宏观环境因素在塑造骨髓恶性肿瘤检测市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解骨髓恶性肿瘤检测市场竞争状况

骨髓恶性肿瘤检测市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵骨髓恶性肿瘤检测市场供应商的绩效评估

FPNV定位矩阵是评估骨髓恶性肿瘤检测市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘骨髓恶性肿瘤检测市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对骨髓恶性肿瘤检测市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告提供了涵盖关键重点领域的市场全面分析：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 人口老化和骨髓恶性肿瘤发生率增加
      • 早期诊断和治疗的趋势
      • 免疫疗法和标靶药物介绍
    • 抑制因素
      • 造血系统恶性治疗费用上涨
    • 机会
      • 强调个人化医疗方法
      • 世界各地的临床试验不断增加
    • 任务
      • 与造血系统恶性相关的副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章骨髓恶性肿瘤检测市场：依产品

  • 消耗品
  • 服务
  • 检测套组

第七章骨髓恶性肿瘤检测市场：依技术分类

  • 萤光原位杂合反应
  • 免疫组织化学
  • 次世代定序
  • 聚合酵素链锁反应

第八章骨髓恶性肿瘤检测市场：依疾病类型

  • 白血病
  • 淋巴瘤
  • 多发性骨髓瘤
  • 骨髓发育不良症候群
  • 骨髓增生性肿瘤

第九章骨髓恶性肿瘤检测市场：依最终用户分类

  • 医院
  • 调查机构
  • 专科诊所

第十章 美洲骨髓恶性肿瘤检测市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太骨髓恶性肿瘤检测市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲骨髓恶性肿瘤检测市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Adaptive Biotechnologies
  • Agilent Technologies, Inc.
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • HORIBA, Ltd.
  • ICON PLC
  • Illumina, Inc.
  • Invitae Corporation
  • Invivoscribe, Inc.
  • Laboratory Corporation of America Holdings
  • Leica Biosystems Nussloch GmbH
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Nikon Instruments
  • Ortho Clinical Diagnostics
  • PerkinElmer Corporation
  • QIAGEN NV
  • Siemens AG
  • Sysmex Corporation
  • Sysmex Inostics Inc.
Product Code: MRR-2E76C3E47FC1

The Hematologic Malignancies Testing Market was valued at USD 3.35 billion in 2023, expected to reach USD 3.60 billion in 2024, and is projected to grow at a CAGR of 7.82%, to USD 5.69 billion by 2030.

The scope of Hematologic Malignancies Testing encompasses a range of diagnostic and monitoring tools designed to identify and characterize blood cancers, including leukemia, lymphoma, and myeloma. These tests are crucial in determining specific cancer types, assessing the disease's progression, and formulating personalized treatment plans, making them indispensable to both healthcare providers and patients. Market application spans clinical diagnostics, research, and personalized medicine, with end-users primarily being hospitals, laboratories, and research institutions. A key growth factor driving the market is the increasing prevalence of hematologic cancers coupled with advancements in genetic and molecular testing techniques. Moreover, a growing focus on personalized medicine and early disease detection bolsters the demand for these tests. Recent technological advancements such as next-generation sequencing and PCR-based methods offer potential opportunities to cater to the rising demand for precise and rapid diagnostics. Companies looking to capitalize on these opportunities should invest in R&D to improve testing accuracy and reduce costs, thereby enhancing accessibility. However, limitations such as high costs of advanced testing equipment, regulatory hurdles, and a need for specialized personnel pose challenges to market growth. Additionally, disparities in healthcare infrastructure and access in emerging markets further impede widespread adoption. Innovation in this space can stem from the development of more cost-effective and portable testing solutions, enhancing point-of-care diagnostics, and integrating AI and machine learning for better data interpretation. The market's evolutionary nature is reflected in its commitment to bridging technological advancements with clinical applications. Businesses should focus on strategic collaborations and continuous innovation in molecular diagnostics, genetic testing, and biosensors to stay competitive, meeting the demand for accuracy and efficiency in cancer diagnostics.

KEY MARKET STATISTICS
Base Year [2023] USD 3.35 billion
Estimated Year [2024] USD 3.60 billion
Forecast Year [2030] USD 5.69 billion
CAGR (%) 7.82%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hematologic Malignancies Testing Market

The Hematologic Malignancies Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising aging population and incidences of hematologic malignancies
    • Inclination toward early diagnosis and treatment
    • Adoption of immunotherapies and targeted drugs
  • Market Restraints
    • High cost of hematologic malignancy treatment
  • Market Opportunities
    • Emphasis on personalized medicine approaches
    • Increasing number of clinical trials globally
  • Market Challenges
    • Adverse effects associated with hematologic malignancies

Porter's Five Forces: A Strategic Tool for Navigating the Hematologic Malignancies Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hematologic Malignancies Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hematologic Malignancies Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hematologic Malignancies Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hematologic Malignancies Testing Market

A detailed market share analysis in the Hematologic Malignancies Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hematologic Malignancies Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hematologic Malignancies Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hematologic Malignancies Testing Market

A strategic analysis of the Hematologic Malignancies Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hematologic Malignancies Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adaptive Biotechnologies, Agilent Technologies, Inc., Beckman Coulter, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., HORIBA, Ltd., ICON PLC, Illumina, Inc., Invitae Corporation, Invivoscribe, Inc., Laboratory Corporation of America Holdings, Leica Biosystems Nussloch GmbH, Myriad Genetics, Inc., Natera, Inc., Nikon Instruments, Ortho Clinical Diagnostics, PerkinElmer Corporation, QIAGEN N.V., Siemens AG, Sysmex Corporation, and Sysmex Inostics Inc..

Market Segmentation & Coverage

This research report categorizes the Hematologic Malignancies Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Consumables, Services, and Testing Kits.
  • Based on Technology, market is studied across Fluorescence In Situ Hybridization, Immunohistochemistry, Next-Generation Sequencing, and Polymerase Chain Reaction.
  • Based on Disease Type, market is studied across Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome, and Myeloproliferative Neoplasms.
  • Based on End-Users, market is studied across Hospitals, Research Institutions, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising aging population and incidences of hematologic malignancies
      • 5.1.1.2. Inclination toward early diagnosis and treatment
      • 5.1.1.3. Adoption of immunotherapies and targeted drugs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of hematologic malignancy treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Emphasis on personalized medicine approaches
      • 5.1.3.2. Increasing number of clinical trials globally
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effects associated with hematologic malignancies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Hematologic Malignancies Testing Market, by Product

  • 6.1. Introduction
  • 6.2. Consumables
  • 6.3. Services
  • 6.4. Testing Kits

7. Hematologic Malignancies Testing Market, by Technology

  • 7.1. Introduction
  • 7.2. Fluorescence In Situ Hybridization
  • 7.3. Immunohistochemistry
  • 7.4. Next-Generation Sequencing
  • 7.5. Polymerase Chain Reaction

8. Hematologic Malignancies Testing Market, by Disease Type

  • 8.1. Introduction
  • 8.2. Leukemia
  • 8.3. Lymphoma
  • 8.4. Multiple Myeloma
  • 8.5. Myelodysplastic Syndrome
  • 8.6. Myeloproliferative Neoplasms

9. Hematologic Malignancies Testing Market, by End-Users

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Research Institutions
  • 9.4. Specialty Clinics

10. Americas Hematologic Malignancies Testing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Hematologic Malignancies Testing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Hematologic Malignancies Testing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Adaptive Biotechnologies
  • 3. Agilent Technologies, Inc.
  • 4. Beckman Coulter, Inc.
  • 5. Becton, Dickinson and Company
  • 6. Bio-Rad Laboratories, Inc.
  • 7. F. Hoffmann-La Roche Ltd.
  • 8. HORIBA, Ltd.
  • 9. ICON PLC
  • 10. Illumina, Inc.
  • 11. Invitae Corporation
  • 12. Invivoscribe, Inc.
  • 13. Laboratory Corporation of America Holdings
  • 14. Leica Biosystems Nussloch GmbH
  • 15. Myriad Genetics, Inc.
  • 16. Natera, Inc.
  • 17. Nikon Instruments
  • 18. Ortho Clinical Diagnostics
  • 19. PerkinElmer Corporation
  • 20. QIAGEN N.V.
  • 21. Siemens AG
  • 22. Sysmex Corporation
  • 23. Sysmex Inostics Inc.

LIST OF FIGURES

  • FIGURE 1. HEMATOLOGIC MALIGNANCIES TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. HEMATOLOGIC MALIGNANCIES TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. HEMATOLOGIC MALIGNANCIES TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HEMATOLOGIC MALIGNANCIES TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HEMATOLOGIC MALIGNANCIES TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TESTING KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MYELODYSPLASTIC SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MYELOPROLIFERATIVE NEOPLASMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 194. HEMATOLOGIC MALIGNANCIES TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 195. HEMATOLOGIC MALIGNANCIES TESTING MARKET, FPNV POSITIONING MATRIX, 2023